review_heavy
Review literature is very dense relative to primary central evidence.
fulltoplow inflation risk
Escherichia coli
ulcerative colitis
Escherichia coli looks like a credible signal in ulcerative colitis, though some caution is still warranted.
Escherichia coli shows a strong literature footprint in ulcerative colitis, with substantial central evidence and broader supporting literature.
escherichia_coli
Credibility score
85
Human translation
3/5
Reproducibility
5/5
Novelty
1/5
Actionability
5/5
Credibility 85Human translation 3/5Reproducibility 5/5Novelty 1/5Actionability 5/5
Why this scores the way it does
- strong central evidence base
- dense review literature
- substantial preclinical support
Main caveats
- directionality and confounding still require curated review
Internal review flags
2 flagssparse_primary_supporting_bucket
Central evidence is high but primary supporting bucket is empty. Classification tiers may still be too coarse.
Primary central evidence
23 papersEnteropathogenic Escherichia coli and ulcerative colitis in cotton-top tamarins (Saguinus oedipus).
2001The Journal of infectious diseases
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Th17 Cell Induction by Adhesion of Microbes to Intestinal Epithelial Cells.
2015Cell
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Sulphate-reducing bacteria from ulcerative colitis patients induce apoptosis of gastrointestinal epithelial cells.
2017Microbial pathogenesis
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis.
2019Cell host & microbe
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Combined Signature of the Fecal Microbiome and Plasma Metabolome in Patients with Ulcerative Colitis.
2019Medical science monitor : international medical journal of experimental and clinical research
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before Diagnosis.
2020Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Mucosal Biofilms Are an Endoscopic Feature of Irritable Bowel Syndrome and Ulcerative Colitis.
2021Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Intestinal flora alterations in patients with ulcerative colitis and their association with inflammation.
2021Experimental and therapeutic medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Identification of gut microbiome and transcriptome changes in ulcerative colitis and pouchitis.
2022Scandinavian journal of gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Prevalence, Abundance, and Virulence of Adherent-Invasive Escherichia coli in Ulcerative Colitis, Colorectal Cancer, and Coeliac Disease.
2022Frontiers in immunology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Overrepresentation of Enterobacteriaceae and Escherichia coli is the major gut microbiome signature in Crohn's disease and ulcerative colitis; a comprehensive metagenomic analysis of IBDMDB datasets.
2022Frontiers in cellular and infection microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Complete Genome Sequences of Extraintestinal Pathogenic Escherichia coli Clinical Isolates from Danish Ulcerative Colitis Patients.
2023Microbiology resource announcements
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Capsulized Fecal Microbiota Transplantation Induces Remission in Patients with Ulcerative Colitis by Gut Microbial Colonization and Metabolite Regulation.
2023Microbiology spectrum
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Differences in gut microbiota and fecal bile acids between Caucasian and Hispanic children and young adults with ulcerative colitis.
2023Physiological reports
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Reduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission.
2023Journal of gastrointestinal and liver diseases : JGLD
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Clinical features and fecal microbiota characteristics of patients with both ulcerative colitis and axial spondyloarthritis.
2024BMC gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Alterations of the Gut Microbiome and TMAO Levels in Patients with Ulcerative Colitis.
2024Journal of clinical medicine
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Draft genome sequences of multi-drug-resistant Escherichia coli strains isolated from ulcerative colitis patients.
2024Microbiology resource announcements
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Structural Variations in Ulcerative Colitis-associated Escherichia coli Reduce Fructose Utilization and Aggravate Inflammation Under High-Fructose Diet.
2025Gastroenterology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Combination of probiotics enhancing butyrogenesis in colonic microbiota model of patients with ulcerative colitis.
2025Applied microbiology and biotechnology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Genetic and Microbial Analysis of Invasiveness for Escherichia coli Strains Associated With Inflammatory Bowel Disease.
2025Cellular and molecular gastroenterology and hepatology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Microbiome multi-omics analysis reveals novel biomarkers and mechanisms linked with CD etiopathology.
2025Biomarker research
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Exploration of fecal microbiota in newly diagnosed patients with inflammatory bowel disease using shotgun metagenomics.
2025Frontiers in cellular and infection microbiology
Direct disease-relevant human paper with strong clinical, biomarker, or mechanistic framing.
Preclinical supporting evidence
23 papersSmoking, humoral immunity, and ulcerative colitis.
1991Gut
Disease-relevant preclinical or model-based paper useful as supporting evidence.
The dual role of Escherichia coli in the course of ulcerative colitis.
2016BMC gastroenterology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Ulcerative Colitis-associated E. coli pathobionts potentiate colitis in susceptible hosts.
2020Gut microbes
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Substantial Intestinal Microbiota Differences Between Patients With Ulcerative Colitis From Ghana and Denmark.
2022Frontiers in cellular and infection microbiology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Fusobacterium nucleatum aggravates ulcerative colitis through promoting gut microbiota dysbiosis and dysmetabolism.
2023Journal of periodontology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Mulberry Anthocyanins Ameliorate DSS-Induced Ulcerative Colitis by Improving Intestinal Barrier Function and Modulating Gut Microbiota.
2022Antioxidants (Basel, Switzerland)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Jatrorrhizine alleviates ulcerative colitis via regulating gut microbiota and NOS2 expression.
2022Gut pathogens
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Deferasirox alleviates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and improving intestinal microbiota.
2023Life sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
κ-Selenocarrageenan Oligosaccharides Prepared by Deep-Sea Enzyme Alleviate Inflammatory Responses and Modulate Gut Microbiota in Ulcerative Colitis Mice.
2023International journal of molecular sciences
Disease-relevant preclinical or model-based paper useful as supporting evidence.
An Intestinal Th17 Subset is Associated with Inflammation in Crohn's Disease and Activated by Adherent-invasive Escherichia coli.
2023Journal of Crohn's & colitis
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Multi-omics analysis reveals the interaction of gut microbiome and host microRNAs in ulcerative colitis.
2023Annals of medicine
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Gut colonization with antibiotic-resistant Escherichia coli pathobionts leads to disease severity in ulcerative colitis.
2024International journal of antimicrobial agents
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Dehydroevodiamine Alleviates Ulcerative Colitis by Inhibiting the PI3K/AKT/NF-κB Signaling Pathway via Targeting AKT1 and Regulating Gut Microbes and Serum Metabolism.
2024Molecules (Basel, Switzerland)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Multi-biome analysis identifies distinct gut microbial signatures and their crosstalk in ulcerative colitis and Crohn's disease.
2024Nature communications
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Luteolin Alleviates Ulcerative Colitis in Mice by Modulating Gut Microbiota and Plasma Metabolism.
2025Nutrients
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Sustained in situ protein production and release in the mammalian gut by an engineered bacteriophage.
2026Nature biotechnology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Thlaspi arvense suppresses gut microbiota related TNF inflammatory pathway to alleviates ulcerative colitis.
2025Frontiers in immunology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Synergistic Genetic and Chemical Engineering of Probiotics for Enhanced Intestinal Microbiota Regulation and Ulcerative Colitis Treatment.
2025Advanced materials (Deerfield Beach, Fla.)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Biosynthesis of Melanin with Engineered Probiotics for Oral Treatment of Ulcerative Colitis.
2025ACS nano
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Beneficial Effects of Apple Polyphenol Extract and Time-Restricted Feeding on Ulcerative Colitis and Accompanying Depression-like Behaviors Are Correlated with Gut-Brain Axis Modulation.
2025Journal of agricultural and food chemistry
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Baicalein ameliorates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and regulating gut microbiota.
2025Frontiers in pharmacology
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Expressing Vitreoscilla hemoglobin in Escherichia coli Nissle 1917 enhances its probiotic potential for alleviating ulcerative colitis.
2025Journal of controlled release : official journal of the Controlled Release Society
Disease-relevant preclinical or model-based paper useful as supporting evidence.
An Inflammation-Targeting Engineered Probiotic Escherichia coli Nissle 1917 with High Anti-TNF-α Nanobody Secretion Efficacy Alleviates Ulcerative Colitis.
2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Disease-relevant preclinical or model-based paper useful as supporting evidence.
Review supporting evidence
22 papersBacterial hemorrhagic enterocolitis.
2003Journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Toxic megacolon.
2012Inflammatory bowel diseases
Relevant review or meta-analysis for the signal-disease area.
Escherichia coli Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis.
2015Journal of gastrointestinal and liver diseases : JGLD
Relevant review or meta-analysis for the signal-disease area.
Probiotics and prebiotics in ulcerative colitis.
2016Best practice & research. Clinical gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.
2016World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Adherent-invasive Escherichia coli in inflammatory bowel disease.
2018Gut
Relevant review or meta-analysis for the signal-disease area.
Influence of Microbiota on Intestinal Immune System in Ulcerative Colitis and Its Intervention.
2017Frontiers in immunology
Relevant review or meta-analysis for the signal-disease area.
Escherichia coli Pathobionts Associated with Inflammatory Bowel Disease.
2019Clinical microbiology reviews
Relevant review or meta-analysis for the signal-disease area.
New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.
2020Autophagy
Relevant review or meta-analysis for the signal-disease area.
Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: A Systematic Review.
2020Gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Phage Therapy in Gastrointestinal Diseases.
2020Microorganisms
Relevant review or meta-analysis for the signal-disease area.
Extracellular vesicles-mediated interaction within intestinal microenvironment in inflammatory bowel disease.
2022Journal of advanced research
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota, inflammatory bowel disease and colorectal cancer.
2022World journal of gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Pathobionts in Inflammatory Bowel Disease: Origins, Underlying Mechanisms, and Implications for Clinical Care.
2024Gastroenterology
Relevant review or meta-analysis for the signal-disease area.
Phage therapy in gut microbiome.
2023Progress in molecular biology and translational science
Relevant review or meta-analysis for the signal-disease area.
The role of the fecal microbiota in inflammatory bowel disease.
2024European journal of gastroenterology & hepatology
Relevant review or meta-analysis for the signal-disease area.
Gut Microbiota Serves as a Crucial Independent Biomarker in Inflammatory Bowel Disease (IBD).
2025International journal of molecular sciences
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota as a mediator of cancer development and management: From colitis to colitis-associated dysplasia and carcinoma.
2025Biochimica et biophysica acta. Reviews on cancer
Relevant review or meta-analysis for the signal-disease area.
Fucoidan as a therapeutic agent for ulcerative colitis: mechanisms of action and modulation of the gut microbiota.
2025Frontiers in cellular and infection microbiology
Relevant review or meta-analysis for the signal-disease area.
The gut immune axis in ulcerative colitis: insights from microbiome research.
2025Molecular biology reports
Relevant review or meta-analysis for the signal-disease area.
Gut microbiota and macrophage crosstalk: implications for colitis-associated colorectal cancer.
2026Frontiers in cellular and infection microbiology
Relevant review or meta-analysis for the signal-disease area.
Escherichia coli and ulcerative colitis.
1997Journal of the Royal Society of Medicine
Relevant review or meta-analysis for the signal-disease area.